Back to top
more

Beam Therapeutics (BEAM)

(Delayed Data from NSDQ)

$24.31 USD

24.31
1,329,789

0.00 (0.00%)

Updated Apr 18, 2024 04:00 PM ET

After-Market: $24.31 0.00 (0.00%) 6:04 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Why Is Beam Therapeutics (BEAM) Down 22.1% Since Last Earnings Report?

Beam Therapeutics (BEAM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Brian Bolan headshot

Brian's Big Idea on Healthcare

Big moving drug stocks and the HealthCare Innovators service at Zacks.

Harmony Biosciences Holdings, Inc. (HRMY) Misses Q4 Earnings and Revenue Estimates

Harmony Biosciences Holdings, Inc. (HRMY) delivered earnings and revenue surprises of -39.19% and 0.14%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Beam Therapeutics Inc. (BEAM) Q4 Earnings Expected to Decline

Beam Therapeutics Inc. (BEAM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kinjel Shah headshot

5 Biotech Stocks Likely to Outpace Q4 Earnings Estimates

Let us look at some drug/biotech stocks, MRNA, BMRN, AMRN, NTLA and BEAM, which are poised to beat on fourth-quarter earnings.

BEAM Stock Rallies More Than 25% in 3 Months: What Next?

BEAM is making good progress with its lead pipeline candidate, BEAM-101, which is being developed for treating sickle cell disease. Also, the recent restructuring efforts are expected to reduce costs.

The Zacks Analyst Blog Highlights bluebird, Editas Medicine, Beam Therapeutics and Intellia Therapeutics

bluebird, Editas Medicine, Beam Therapeutics and Intellia Therapeutics are part of the Zacks top Analyst Blog.

Ekta Bagri headshot

3 Biotechs With Promising Gene Therapies in the Spotlight

The recent FDA approval of two gene therapies has put the focus on biotechs like EDIT, BEAM and NTLA, which have promising candidates in their pipeline.

Why Is Beam Therapeutics Inc. (BEAM) Up 29.5% Since Last Earnings Report?

Beam Therapeutics Inc. (BEAM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Wall Street Analysts Believe Beam Therapeutics Inc. (BEAM) Could Rally 81.29%: Here's is How to Trade

The mean of analysts' price targets for Beam Therapeutics Inc. (BEAM) points to an 81.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

What Makes Beam Therapeutics Inc. (BEAM) a New Buy Stock

Beam Therapeutics Inc. (BEAM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Does Beam Therapeutics Inc. (BEAM) Have the Potential to Rally 139.76% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 139.8% in Beam Therapeutics Inc. (BEAM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Beam Therapeutics (BEAM) Q3 Earnings & Revenues Beat Estimates

Beam Therapeutics' (BEAM) third-quarter 2023 earnings and revenues surpass expectations. The company focuses on developing genome-editing candidate, BEAM-101.

DaVita (DVA) to Report Q3 Earnings: What's in the Offing?

Improvement in U.S. dialysis treatments per day and cost-saving initiatives are likely to have boosted DaVita's (DVA) top line in the third quarter.

Will CRISPR Therapeutics AG (CRSP) Report Negative Q3 Earnings? What You Should Know

CRISPR Therapeutics AG (CRSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Beam Therapeutics Inc. (BEAM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Beam Therapeutics Inc. (BEAM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Zacks Analyst Blog Highlights Bristol Myers, PTC Therapeutics, Beam Therapeutics and BioMarin Pharmaceutical

Bristol Myers, PTC Therapeutics, Beam Therapeutics and BioMarin Pharmaceutical are included in this Analyst Blog.

Biotech Stock Roundup: BMY's Q3 Results, PTCT Up on Deal, BEAM's Restructuring News

Earnings and other updates from Bristol Myers (BMY) and PTC Therapeutic (PTCT) are in focus in the biotech sector.

BEAM to Reprioritize Portfolio, Slash Jobs, Shares Tank

BEAM announces a restructuring and portfolio reprioritization plan to focus on genome-editing candidate, BEAM-101. The company is set to reduce its workforce by almost 20%. Shares fall.

BEAM Focuses on Developing Gene Drug for Growth

While BEAM's pipeline candidates are in early-stage clinical studies, their development is progressing well. Collaborations are a primary source of revenues in the absence of a marketed product.

Down -20.85% in 4 Weeks, Here's Why Beam Therapeutics Inc. (BEAM) Looks Ripe for a Turnaround

Beam Therapeutics Inc. (BEAM) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Tops Revenue Estimates

Beam Therapeutics Inc. (BEAM) delivered earnings and revenue surprises of 21.74% and 39.60%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Tops Revenue Estimates

Beam Therapeutics Inc. (BEAM) delivered earnings and revenue surprises of 2.21% and 67.99%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Tops Revenue Estimates

Nurix Therapeutics, Inc. (NRIX) delivered earnings and revenue surprises of 16.67% and 20.91%, respectively, for the quarter ended February 2023. Do the numbers hold clues to what lies ahead for the stock?

Beam Therapeutics Inc. (BEAM) Reports Q4 Loss, Tops Revenue Estimates

Beam Therapeutics Inc. (BEAM) delivered earnings and revenue surprises of 59.09% and 69.94%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?